Engineered immune cells and vaccine take aim at Hard-to-Treat cancers

This early-phase trial tests a treatment for adults with certain advanced solid tumors (like colorectal, lung, or breast cancer) that have spread and stopped responding to standard therapy. The approach uses a person's own white blood cells, which are genetically modified in a lab to recognize and attack cancer cells carrying a specific KRAS mutation, then given back along with a vaccine to boost their activity. Participants receive chemotherapy beforehand to prepare the body, stay in the hospital for 3-4 weeks, and are followed for up to 15 years to monitor safety and tumor response.